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Epilepsy is a neurodegenerative brain disorder characterized by recurrent seizure attacks. Numerous studies have suggested a strong
correlation between oxidative stress and neuroinﬂammation in several neurodegenerative disorders including epilepsy. This study
is aimed at investigating the neuroprotective eﬀects of the natural compound carveol against pentylenetetrazole- (PTZ-) induced
kindling and seizure model. Two diﬀerent doses of carveol (10 mg/kg and 20 mg/kg) were administered to male rats to
determine the eﬀects and the eﬀective dose of carveol and to further demonstrate the mechanism of action of nuclear factor E2related factor (Nrf2) in PTZ-induced kindling model. Our results demonstrated reduced levels of innate antioxidants such as
superoxide dismutase (SOD), catalase, glutathione-S-transferase (GST), and glutathione (GSH), associated with elevated lipid
peroxidation (LPO) and inﬂammatory cytokines level such as tumor necrosis factor-alpha (TNF-α), and mediators like
cyclooxygenase (COX-2) and nuclear factor kappa B (NFκB). These detrimental eﬀects exacerbated oxidative stress and
provoked a marked neuronal alteration in the cortex and hippocampus of PTZ-intoxicated animals that were associated with
upregulated Nrf2 gene expression. Furthermore, carveol treatment positively modulated the antioxidant gene Nrf2 and its
downstream target HO-1. To further investigate the role of Nrf2, an inhibitor of Nrf2 called all-trans retinoic acid (ATRA) was
used, which further exacerbated PTZ toxicity. Moreover, carveol treatment induced cholinergic system activation by mitigating
acetylcholinesterase level which is further linked to attenuated neuroinﬂammatory cascade. The extent of blood-brain barrier
disruption was evaluated based on vascular endothelial growth factor (VEGF) expression. Taken together, our ﬁndings suggest
that carveol acts as an Nrf2 activator and therefore induces downstream antioxidants and mitigates inﬂammatory insults
through multiple pathways. This eventually alleviates PTZ-induced neuroinﬂammation and neurodegeneration.
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1. Introduction
Epilepsy, which aﬀects nearly 65 million people worldwide,
is among the most prevalent neurodegenerative disease
after stroke [1]. It is a syndrome characterized by various
neurological conditions, including recurrent epileptic seizures, cognitive deﬁcits, behavioral impairments, and electroencephalographic changes. Epilepsy is most often
aggravated by psychiatric comorbidities, like memory and
learning deﬁcits, which aﬀect about 30% of the population
[2]. Although transient abnormal cortical nerve stimulation
can lead to seizure formation, there are numerous other contributing factors having a role in seizure generation, such as
excitotoxicity, mitochondrial dysfunction, altered cytokine
levels, oxidative and endoplasmic reticulum stress, and
genetic factors [3–5]. The clinical use of existing antiepileptic
drugs (AEDs) is compromised due to frequent onset of
adverse eﬀects along with chronic toxicities of the vital
organs [6–8]. Therefore, an in-depth understanding of the
mechanisms underlying this disease is required to develop
alternative better treatment choices.
Multiple studies have proposed that oxidative stress and
inﬂammation can exacerbate the severity of epilepsy [9, 10]
as a consistently high level of inﬂammatory cytokines is found
in seizure pathophysiology [11]. These anomalies can lead to
numerous functional and biochemical alterations, including
lipid peroxidation (LPO), BBB disruption, and angiogenesis
[12, 13]. Moreover, the surge in cytokines is directly related
to the permeation of leukocytes and granulocytes to the brain
from the surrounding vasculature [14]. Furthermore, resident
glial cells are rapidly activated and trigger the release of proinﬂammatory cytokines such as interleukin-1 (IL-1β), tumor
necrotic factor-alpha (TNF-α), and interleukin-6 (IL-6),
which clinically compromise the prognosis of epilepsy [15,
16]. Pentylenetetrazole (PTZ), which is a GABA receptor
antagonist, is a widely accepted and established model for
inducing epileptic seizures via blockade of the gammaaminobutyric acid (GABA) receptor, a major inhibitory neurotransmitter in the brain [17]. PTZ exerts a convulsant eﬀect
similar to that of human absence seizure and can be used for
generating rodent epileptic model [18–20]. Multiple studies
have suggested elevated NO levels and reduced antioxidant
activity in the rat brain after PTZ treatment [21, 22]. Therefore, maintaining low ROS/RNS levels in the brain is crucial
for normal cellular function as it facilitates ablation of subsequent neuroinﬂammation [23].
Nuclear factor erythroid 2-related factor 2 (Nrf2, or
NFE2L2) is critically involved in the natural cellular defense
system, as it governs the gene expression of numerous antioxidant proteins and ROS-eliminating enzymes, thereby
preventing ROS-induced neuronal and cellular damage
[24]. Upon activation, Nrf2 activates the innate antioxidant
cellular machinery and upregulates multiple inducible antioxidant enzymes, including heme-oxygenase-1 (HO-1),
NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione
peroxidase (GPx), catalase, and superoxide dismutase
(SOD) [25]. There is evidence suggesting the crosstalk
between Nrf2 and NF-κB, which reveals the mechanism
through which activated Nrf2 exerts an anti-inﬂammatory
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Figure 1: Structure of carveol.

eﬀect [26–29]. Moreover, previous studies demonstrated
the neuroprotective role of Nrf2 not only in laboratory animals but also in human brain samples [30–32]. We have previously shown that activation of Nrf2 signaling attenuated
infarction area and inﬂammatory-related pathologies not
only in stroke but also in the depression model [33–35].
Therefore, Nrf2 may be a suitable therapeutic target for managing epilepsy and seizures.
Natural moieties are an attractive source of new drugs,
owing to their rich antioxidant potential. Several natural drugs
have shown protective potential against a variety of mediators,
including free radicals and inﬂammatory factors [36, 37]. Carveol is a natural monocyclic monoterpenoid antioxidant compound (Figure 1) that is abundant in caraway seeds, mandarin,
black tea, dill, and essential oils of orange peel [38, 39]. Carveol
has been reported in traditional Chinese medicine as an antispasmodic, carminative, astringent, and further used for indigestion and dyspepsia [40]. We previously demonstrated the
neuroprotective potential of carveol in ischemic brain injury
by attenuating infarction area [33]. In another study, carveol
mitigated hepatocellular necrosis by showing antioxidant, antihyperlipidemic, and anti-inﬂammatory activities [41]. Furthermore, carveol exhibited promising results in the management
of diabetes [42]. Given the strong antioxidant potential of carveol and its promising properties, this study is aimed at evaluating whether carveol administration can ameliorate PTZinduced epileptogenesis in a rat model by modulating the
Nrf2 pathway.

2. Materials and Methods
2.1. Chemicals and Reagents. Carveol (#192384, PubChem
ID:24851543), a mixture of isomers, with 97% purity, and
3,3-diaminobenzidine tetrahydrochloride hydrate (#D5637,
PubChem ID:57654109) were purchased from SigmaAldrich (USA). Mouse monoclonal anti-p-NF-κB (SC271908), mouse monoclonal anti-TNF-α (SC-52B83), mouse
monoclonal anti-HO-1 (SC-136960), rabbit polyclonal antiNrf2 (SC-722), mouse monoclonal anti-VEGF (SC-7269),
and ABC Elite kit (SC-516216) were purchased from Santa
Cruz Biotechnology, Dallas, TX, USA). Rat ELISA kits p-NFκB (SU-B28069) and TNF-α ELISA kit (SU-B3098) were procured from Shanghai Yuchun Biotechnology, Shanghai,
China, while rat COX-2 (E-EL-M0959) was purchased from
Elabscience Biotechnology Inc., Houston, TX, USA. The
horseradish peroxidase-conjugated secondary antibody (ab6789) was obtained from Abcam (Cambridge, UK). Proteinase
K (#02193981-CF) was obtained from MP Bio USA. All other
solvents and reagents as DPX Mounting media (#06522), 5,5 ′
-dithiobis (2-nitrobenzoic acid) (DTNB, #D8130, PubChem
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ID:24894189), trichloroacetic acid (TCA, #T6399, PubChem
ID:24900373), and N-(1-naphthyl) ethylenediamine dihydrochloride (#222488, PubChem ID:24853334) were procured
from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Animals and Ethical Approval. Adult male SpragueDawley rats (weight 250–300 g) were habituated under laboratory conditions at 25°C for 7 days, with 12 h alternating light
and dark cycles; moreover, they received standard commercial
diet and water ad libitum. All experimental procedures were
conducted following the ARRIVE guidelines and approved
by the Research and Ethical Committee (REC) of the Riphah
Institute of Pharmaceutical Sciences (Approval ID: Ref. No.
REC/RIPS/2018/14; date of approval: November 15, 2018).
2.3. Acute Toxicity Testing. To determine the acute toxicity of
the selected natural compound, we included 10 nonpregnant
nulliparous female rats and divided them into the control
and treatment groups (each n = 5). After being deprived of
food and water overnight, one rat was administered a limited
oral dose of 2000 mg/kg per OECD guidelines 425 on the
next day [43, 44]. After being observed for 24 h and survival
being conﬁrmed, the same protocol was followed for the
remaining rats in the treatment group. They were initially
observed for 48 h for any signs of distress and mortality; subsequently, they were observed daily for 14 days for other toxicity signs, including squinted eyes, writhing, salivation,
tremors, convulsions, loss of fur, change in overall behavior,
stress, and mortality. On the 15th day, blood samples were
obtained from animals via cardiac puncture for various biochemical analyses, including wet organ weight, antioxidant
proﬁle, liver function tests, renal function tests, and hematological proﬁle. Subsequently, the animals were sacriﬁced
under anesthesia, and vital organs were collected for histopathological examination.
2.4. Seizure Induction Using PTZ. Seizures were induced as
previously described, with slight modiﬁcations [45, 46].
Brieﬂy, PTZ was dissolved in normal saline and intraperitoneally (IP) injected into the PTZ-kindled group at a subconvulsive dose of 40 mg/kg at 48 h intervals for 15 days until
they were fully kindled and showed stage 5 or 6 on three consecutive injections. Only successfully kindled animals were
included in the study.
2.5. Study Design and Animal Treatment. Animals were randomly divided into seven groups (n = 10, each group) as follows: group 1 (control group): saline injection containing 5%
DMSO were administered at 48 h intervals for 15 days; group
2 (PTZ control group): 40 mg/kg PTZ administered until
stage 5 convulsions, with eight injections being administered;
group 3/4 (treated group): rats received protective doses of
carveol 10 (Car-10) and 20 mg/kg (Car-20) and were
administered 30 min before PTZ; group 5 (ATRA+PTZ
group): rats were treated with 5 mg/kg all-trans retinoic
acid (ATRA) and were administered 30 min before PTZ;
group 6 (ATRA+PTZ+Car): rats were treated with ATRA
30 mins before giving carveol and PTZ was administered
30 mins after carveol treatment, followed by behavior recording for 30 min; group 7 (standard group): rats were treated
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with 2 mg/kg diazepam at 30 min before PTZ administration.
Carveol, ATRA, PTZ, and diazepam were dissolved in normal saline containing 5% DMSO and were administered for
15 days at a 48 h interval (Figure 2). Notably, the selected carveol dose was determined in a previous study using a neurodegenerative model established in our lab [33].
2.6. Evaluation of Behavioral Characteristics
2.6.1. Racine’s Scale. Seizure activity was evaluated for 30 min
after each PTZ administration. Behavioral characteristics,
including latency, intensity, and convulsion stage, were
recorded for 30 min after each PTZ dose using the modiﬁed
Racine scale [47]: stage 0—no response; stage 1—hyperactivity, restlessness, and vibrissae twitching; stage 2—head nodding, head clonus, and myoclonic jerks; stage 3—unilateral
or bilateral limb clonus; stage 4—forelimb clonic seizures;
stage 5—generalized clonic seizures with falling; stage
6—hind limb extensor; and stage 7—death (Table 1). We calculated the mean seizure intensity by taking the mean of all
individual seizure scores and dividing them by the number
of animals, followed by plotting against the treatment duration. Seizure latency was measured as the duration between
PTZ administration and the appearance of the ﬁrst clonic seizure, jerky body movement, or sudden twitch. Seizure frequency was calculated as the number of seizures
experienced by the animal within 30 min of PTZ administration, regardless of the seizure stage. Animals were considered
kindled when they reached stage 5 (clonic-tonic seizures) or
6, after three consecutive PTZ injections at 48 h intervals.
The investigator who performed behavioral trials was
blinded from the group allocation to avoid any bias.
2.6.2. Morris Water Maze (MWM) Test. The MWM test was
performed to assess the cognitive deﬁcits and spatial learning
ability of the rats as previously discussed [47]. The MWM is
comprised of a circular pool with a height and diameter of 50
cm and 120 cm, respectively. The pool was hypothetically
divided into four quadrants with reference to the target quadrant. The quadrant where the probe or the elevated platform
(placed 1 cm beneath the water) was placed was tagged as
the target quadrant and then the right-left and opposite quadrant. The water temperature was maintained at 25° C ± 1° C,
the position of the platform was ﬁxed, and each time, rats were
dropped from diﬀerent quadrants. A blind observer recorded
the escape latency period, i.e., the time taken by the rat to
locate and climb the raised platform. The experiment lasted
for four days. In the training sessions, the rats were trained
to locate and climb the raised platform with a staying time
of 5-7 s. The observer recorded the time when the animal
was dropped into the water, and if the rat failed to locate the
platform within 90 s, the observer manually guided the rat to
the platform. The training session was conducted twice a day
at 25 min intervals. Similarly, the escape latency interval for
each rat was observed and recorded in each training session
during the three days of the testing sessions. A decrease in
escape latency was considered to indicate neurodegeneration.
On the last day of behavior analysis, we performed a probe
test to check the spatial memory. The probe was removed
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Figure 2: Diagrammatic illustration of the experimental protocol. The treatment protocol was performed for 15 days. In all these groups, a
loading dose of PTZ (40 mg/kg, IP) was injected 30 mins after drug treatment (ATRA, carveol, or diazepam), except in the saline group. Brain
tissues were collected after 24 h of the last dose for further analysis.
Table 1: Modiﬁed Racine’s scale.
Stages
0
1
2
3
4
5
6
7

Seizure intensity
No response
Hyperactivity, restlessness, and vibrissae twitching
Head nodding, head clonus, and myoclonic jerks
Unilateral or bilateral limb clonus
Forelimb clonic seizures
Generalized clonic seizures with falling
Hind limb extensor
Death

from the target quadrant, and rats were dropped opposite to
the target quadrant, with the time spent in each quadrant
being recorded for 60 s. The percentage of time spent in the
target quadrant was considered a measure of the extent of neurodegenerative potential and memory function.
2.7. Tissue Collection and Histological Preparation. At 24 h
after the last PTZ administration, the rats were quickly decapitated, and their brains were removed on an ice-cold glass
plate. The hippocampus and cortex were separated; subsequently, half of the samples were stored at -80°C for biochem-

ical processing while the other half was kept in 4% formalin
solution for histopathological and immunohistochemical
analysis. Brain tissue samples were homogenized using 0.1 M
sodium phosphate buﬀer (pH 7.4) containing phenylmethylsulfonyl ﬂuoride (PMSF) as a protease inhibitor. Subsequently,
samples were centrifuged at 4000×g for 10 min at 4°C, and the
supernatant was used for various biochemical assays.
2.8. Estimation of Brain Acetylcholinesterase (AChE) Activity.
Brain AChE activity was determined as previously described
by Ellman et al. (1961), with slight modiﬁcations [48]. Brieﬂy,
100 μL of DTNB reagent (0.1 mM) was added to 2.6 mL of
phosphate buﬀer (pH 7.4); subsequently, 0.4 mL of brain tissue
homogenate was added to this mixture. The initial reading of
this reaction mixture was taken at 412 nm before substrate
addition. Next, 20 μL of the substrate (acetylcholine iodide, 1
mM) was added to this mixture, and the absorbance was
recorded every 10 min for 20 min. The mean change in the
absorbance was calculated as follows:
R = 5:74 × 10 − 4 ×
A = change in absorbance per minute.

A
,
Co

ð1Þ
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R = rate of moles of acetylthiocholine iodide hydrolyzed
per min/g of brain tissue.
Co = original concentration.
Enzyme activity was expressed as μmoles of acetylcholine
hydrolyzed per milligram of protein.
2.9. Antioxidant Assays
2.9.1. Reduced Glutathione (GSH) Activity. GSH was determined to estimate the degree of PTZ-induced oxidative damage and the resulting eﬀect of carveol as previously discussed
[34]. We mixed 0.2 mL of the tissue supernatant with 2 mL of
DTNB mixture, followed by the addition of 0.2 M phosphate
buﬀer to yield a ﬁnal volume of 3 mL. The absorbance was
measured after 10 min using a spectrophotometer at 412
nm, where phosphate buﬀer and DTNB solution were used
as a blank and control, respectively. The real absorbance
value was obtained by subtracting the absorbance of the control from that of the tissue lysate. The ﬁnal GSH activity was
expressed in units of μmol/mg of protein.
2.9.2. Glutathione-S-Transferase (GST) Activity. To calculate
GST activity, we freshly prepared 1 mM CDNB and 5 mM
GSH solutions in 0.1 M phosphate buﬀer. Three replicates
of the 1.2 mL reaction mixture were kept in glass vials,
followed by the addition of 60 μL of tissue homogenate to
each of these mixtures. The blank contained water rather
than tissue lysate. Next, 210 μL aliquots from the reaction
mixture were pipetted out in a microtiter plate; further,
absorbance was measured at 340 nm for 5 min at 23°C using
an ELISA plate reader (BioTek ELx808, Winooski, VT, USA).
GST activity was expressed in units of μmol of CDNB conjugate/min/mg of protein [49, 50].
2.9.3. Superoxide Dismutase (SOD) Activity. We mixed 0.1
mL of tissue homogenate with 0.1 mL of pyrogallol solution
(1 M) and 2.8 mL of 0.1 M potassium phosphate buﬀer (pH
7.4), which yielded a reaction mixture of 3 mL. The absorbance was measured at 312 nm [51]. SOD activity was
expressed in U/mg of protein.
2.9.4. Catalase (CAT) Activity. We added 0.05 mL of tissue
homogenate to 1.95 mL of phosphate buﬀer (50 mM, pH 7)
and 1 mL of H2O2 solution (30 mM). The absorbance of the
ﬁnal mixture was measured at a wavelength of 240 nm. The
catalase activity was calculated using the following formula:
CAT = δO:D ÷ E × Volume of sampleðmLÞ × proteinðmgÞ,
ð2Þ
where δO:D represents the change in absorbance per minute
and E represents the extinction coeﬃcient of H2O2 with a
value of 0.071 mmol cm−1 [51]. The Lowery method was used
to measure protein levels. Catalase activity was expressed as
μmol of H2O2/min/mg of protein.
2.9.5. Determination of Lipid Peroxidation (LPO). The extent
of LPO was estimated by detecting thiobarbituric acid reactive substances (TBARS), as previously described with slight
modiﬁcations [52]. The assay mixture contained 580 μL of

phosphate buﬀer (0.1 M, pH 7.4), 200 μL of supernatant, 20
μL of ferric chloride, and 200 μL of ascorbic acid (100 mM).
The mixture was incubated in a water bath at 37°C for 60
min. Next, the reaction was stopped by adding 1000 μL of trichloroacetic acid (10% TCA) and 1000 μL of thiobarbituric
acid (0.66% TBA) to the samples. The tubes were kept in a
water bath for 20 min, cooled in an ice bath, and centrifuged
at 3000×g for 10 min. The absorbance of the supernatant and
blank containing all reagents except the test drug was measured at 535 nm and expressed as TBARS- nmol/mg protein.
2.10. Histological Preparation. Following brain extraction,
the tissue was stored in 4% paraformaldehyde solution,
washed, and cut into 3 mm thick coronal sections using a
sharp blade. Subsequently, these sections were ﬁxed in parafﬁn blocks and sliced into 4 μm thin coronal sections using a
microtome [53]. These sections were processed using the following staining techniques.
2.11. Hematoxylin and Eosin Staining (H&E Staining). Our
previous lab protocols were used for H&E staining [54].
Brieﬂy, tissue-coated slides were deparaﬃnized using absolute xylene followed by a graded alcohol solution. Next, the
slides were stained by immersion in hematoxylin solution
until the stain was retained in the nucleus. After treatment
with 1% HCl and 1% ammonia water, the slides were treated
with eosin solution for a few minutes and then air-dried.
After dehydration with graded ethanol and xylene, as well
as coverslipping, ﬁve images per slide were captured under
an Olympus light microscope (Olympus, Japan) and analyzed using the ImageJ software. Histopathological changes
in cellular morphology, shape, number, and edema were
determined using light microscopy.
2.12. Immunohistochemical Analysis. Immunostaining was
performed as previously discussed [55]. First, the tissue was
rehydrated using xylene, graded alcohol series, and distilled
water, followed by washing three times with PBS for 5 min.
Proteinase K was used as the antigen recovery step. After
washing, the tissue was treated with 3% H2O2 solution for
5 min to prevent endogenous peroxidase activity. Next,
blocking serum was applied at room temperature for a minimum of 1 h to ensure blocking of areas outside the antigenic
areas. The slides were then treated with anti-rabbit Nrf2 antibody, anti-mouse VEGF antibody, anti-mouse HO-1 antibody, anti-mouse p-NF-κB antibody, and anti-mouse TNFα antibody (dilution 1 : 100, Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4°C. The next day, the slides were
initially treated with a secondary antibody for 2 h after washing with PBS. Next, the slides were treated with an ABC
staining kit and left for 1 h. Finally, the slides were stained
with DAB solution for 5 min, washed with water, dipped in
xylene and 100% ethanol, and covered using mounting
media. The slides were air-dried for a minimum of one day
with images being obtained using an Olympus microscope
and evaluated using ImageJ software. The slides were
observed at 10x and 40x magniﬁcation; additionally, ﬁve random overlapping sections were chosen to calculate the number of stained neurons in the cortex and hippocampal CA1,
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CA2, and DG granule cells. The means were plotted against
the groups.
2.13. ELISA (Enzyme-Linked Immunosorbent Assay). COX-2,
p-NF-κB, and TNF-α expression were quantiﬁed using rat
ELISA kits following the manufacturer’s instructions. Brieﬂy,
an appropriate quantity of brain tissue (50 mg) was homogenized using a Heidolph crusher at 15,000 rpm in 2500 μL PBS
containing PMSF as the protease inhibitor [56]. Next, the tissue homogenate was centrifuged at 4000×g for 10 min, and
the supernatant was collected. Total protein concentration
in the supernatant of each group was calculated using the
BCA method (Elabscience); moreover, an equivalent protein
quantity was used to quantify the protein concentration of
COX-2, p-NF-κB, and TNF-α using an ELISA microplate
reader (BioTek EL×808). Finally, the protein concentration
(pg/mL) was normalized to the total protein content (pg/mg
total protein).
2.14. Real-Time Polymerase Chain Reaction (RT-PCR). TRIzol was used to extract the total RNA amount in freshly isolated brain tissues as previously discussed [57]. RNA quality
and quantity were assessed using a NanoDrop plate (Skanit
RE 4.1, Thermo Scientiﬁc). To convert RNA to cDNA, we
used a viva cDNA synthesis kit (Vivantis cDSK01-050). Polymerase chain reactions were performed on a Galaxy XP
Thermal Cycler (BIOER, PRC) and 2X Amplifyme Universal
qPCR mix (Blirt, Germany), following the manufacturer’s
speciﬁcations. The sequences of forwarding and reverse
primers were as follows: Rat_Nrf2_Forward: CACATCCAG
ACAGACACCAGT and Rat_Nrf2_Reverse: CTACAAATG
GGAATGTCTCTGC; Rat_HO-1-Forward: CGTGCAGAG
AATTCTGAGTTC and Rat_HO-1-Reverse: AGACGCTTT
ACGTAGTGCTG; Rat_GAPDH-Forward: CGTGCAGAG
AATTCTGAGTTC and Rat_GAPDH-Reverse: TTCAGG
TGAGCCCCAGCCTT. The relative gene expression of
Nrf2 was determined using the 2−ΔΔCT method for real-time
quantitative PCR.
2.15. Statistical Analysis. Statistical analysis was performed
using the GraphPad prism-8 software. Neurobehavior and
oxidative data were analyzed using one-way analysis of variance (ANOVA) followed by a post hoc Bonferroni multiple
comparison test. The other data were interpreted using
two-way ANOVA followed by post hoc Bonferroni multiple
comparison tests. ImageJ software was used to analyze morphological data. Statistical signiﬁcance was set at p < 0:05.
Symbol ∗ or # represents p < 0:05; ∗∗ or ## represents p <
0:01; and ∗∗∗ or ### represents p < 0:001. Finally, ∗ and # represent signiﬁcant diﬀerences relative to saline and disease,
respectively. All data are expressed as the mean ± standard
error of the mean (SEM).

3. Results
3.1. Acute Oral Toxicity Testing of Carveol. To assess the
safety proﬁle of carveol, OECD guidelines 425 were followed.
Fur and skin, fecal consistency, urine color, respiration, and
sleep patterns were found to be normal after administration
of 2000 mg/kg of carveol. All animals in both groups sur-
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vived, with none showing signs of convulsions or distress.
Both groups showed normal weight progression during the
14-day protocol. There were no alterations in antioxidant
proﬁle, liver function tests, kidney function tests, and hematological indices (Suplementary Figures S1and S2).
Histopathological screening of vital organs, including the
brain, liver, kidney, and heart, revealed no signs of
vacuolation, dystrophy, and/or atrophy (Figure 3). A
detailed toxicity proﬁle of carveol indicated that it was safe
up to a dose of 2000 mg/kg.
3.2. Anticonvulsant Eﬀect of Carveol on PTZ-Induced SeizureLike Behavior. PTZ-treated animals presented signiﬁcant
generalized tonic-clonic convulsions also called epileptogenesis, and it corresponds to stage 6 and/or 7 of Racine’s scale,
as indicated by the signiﬁcant mean seizure intensity score
relative to the saline group (Figure 4(a), ∗∗∗ p < 0:001). Similarly, PTZ signiﬁcantly increased the seizure frequency on the
15th day of administration (Figure 4(b), ∗∗∗ p < 0:001) with a
corresponding very short latency time, which depicts rapid
seizure initiation on successive PTZ administration
(Figure 4(c)). Overall, animals subjected to PTZ kindling
exhibited a percentage survival of 71.4% (Figure 4(d)). Carveol treatment (10 mg/kg) reversed the PTZ-induced behavioral deﬁcits, as indicated by the signiﬁcantly low mean
seizure intensity score (Figure 4(a), ##p < 0:01). Moreover,
carveol signiﬁcantly reduced seizure frequency (Figure 4(b),
##
p < 0:01) and was associated with an extended latency time
(Figure 4(c), ##p < 0:01). Additionally, the percentage survival improved to 85% compared with PTZ (Figure 4(d),
##
p < 0:01). Similarly, carveol at a dose of 20 mg/kg showed
similar protection given that none of the animals exhibited
a seizure score of 4–5 (Figure 4(a), ###p < 0:001) during the
whole kindling period; moreover, there was a signiﬁcantly
reduced seizure frequency (Figure 4(b), ##p < 0:01) and an
extended latency period (Figure 4(c), ###p < 0:001). Diazepam showed similar protection to Car-20 (###p < 0:001).
Moreover, cotreatment with PTZ and ATRA further aggravated seizure-like behavioral deﬁcits, which could not be mitigated by carveol treatment, indicating the termination of
carveol activity by ATRA administration.
3.3. Carveol Attenuated Cognitive Impairment and Memory
Dysfunction in Epileptic Rats. MWM test was used to assess
the eﬀect of carveol on memory and cognition in PTZinduced epileptic rats. In the hidden-platform swimming
test, PTZ-treated rats exhibited a higher latency time compared with saline-treated rats, which indicated severe memory deﬁcits (Figure 5(a), ∗∗∗ p < 0:001). Carveol treatment
with 10 and 20 mg/kg doses signiﬁcantly improved memory
deﬁcits and improved the latency time to reach the hidden
platform (Figure 5(a), ###p < 0:001). To assess reference
memory, a probe trial was conducted 24 h after the last acquisition period. Figure 5(b) shows the time spent by each group
of rats in speciﬁc quadrants. Increased time spent in quadrants other than the target quadrant is indicative of impaired
spatial learning, as observed in the PTZ-kindled group
(Figures 5(b) and 5(c), ∗∗∗ p < 0:001, ∗∗ p < 0:01). Upon treatment with 10 mg/kg carveol, the animals displayed
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signiﬁcantly improved spatial memory and learning
(Figures 5(b) and 5(c), #p < 0:05, ##p < 0:01). Similarly,
20 mg/kg carveol signiﬁcantly improved spatial memory
and learning compared with the PTZ-treated animals

(Figures 5(b) and 5(c), ###p < 0:001). Additionally, carveol
treatment did not improve the ATRA-treated group,
which indicated cessation of carveol activity by ATRA
administration.
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Figure 5: Eﬀect of carveol on PTZ-induced memory impairment and neuronal survival. (a) The latency time of rats on the hidden platform.
(b) Time spent by PTZ-treated rats in each quadrant in the probe test on the 5th day. (c) The percentage time spent by animals in the target
quadrant, with n = 10/group. (d) Representative photomicrographs of the H&E-stained cortex and hippocampal tissue revealing the presence
of kryolitic and atrophied nuclei in PTZ-kindled animals while the Car-20 group showed only a few cells with degenerative signs (40x, scale
bar 50 μm). All data were expressed as mean ± SEM (n = 5/group). ∗∗∗ p < 0:001 denotes a signiﬁcant diﬀerence compared with the saline
group. ###p < 0:001 denotes a signiﬁcant diﬀerence compared with the PTZ-kindled group.

To further validate our hypothesis, we examined morphological changes in the cortical and hippocampal regions
using H&E staining. The saline group showed round, welldemarcated intact cells without nuclear condensation or distortion with a basophilic cytoplasm (Figure 5(d)). The PTZ-

treated group showed signiﬁcant histopathological alterations, including altered neuronal shape and size, as well as
other atypical features, including swollen, ﬂattened, atrophied, and kryolitic neurons with pyknotic nuclei
(Figure 5(d)). Examination of cortical and hippocampal areas
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Figure 6: Carveol augments the antioxidant capacity of the brain via the Nrf2 signaling pathway. (a) Nrf2 gene expression as quantiﬁed by
RT-PCR with (n = 5/group). (b) Immunohistochemistry results for Nrf2 in the cortical and hippocampal tissues. Histograms exhibit
higher Nrf2 nuclear localization in treated brain tissues. Scale bar 50 μm, magniﬁcation 40x (n = 5/group. (c) HO-1 expression as
quantiﬁed by RT-PCR with (n = 5/group). (d) Immunohistochemistry results for HO-1 in the cortical and hippocampal tissues.
Histograms exhibit higher HO-1 nuclear localization in treated brain tissues. Scale bar 50 μm, magniﬁcation 40x (n = 5/group). ∗∗∗ p <
0:001 indicates signiﬁcant diﬀerence relative to saline, while ###p < 0:001 shows signiﬁcant diﬀerence compared with the PTZ group. All
data are presented as means ± SEM.

conﬁrmed that carveol (20 mg/kg) signiﬁcantly ameliorated
these morphological damages, as indicated by an increase
in the number of intact neurons and cell count
(Figure 5(d), cortex: ###p < 0:001, CA1 and DG: ###p < 0:001
, CA3: ##p < 0:01). Additionally, carveol pretreatment in the
ATRA-treated group did not improve PTZ-induced histopathological damage.
3.4. Carveol Augments the Antioxidant Capacity of the Brain
through Nrf2 and Nrf2-Dependant Downstream Antioxidant
HO-1. Nrf2 combines with free radicals and executes vital
antioxidative functions. To further investigate the antioxidant
potential of carveol, we analyzed the expression of the Nrf2
gene and the downstream HO-1. RT-PCR analysis indicated
upregulated Nrf2 expression in the PTZ-treated group given
that PTZ kindling exerted enough oxidative stress in the brain
to activate the body’s innate antioxidant Nrf2 (Figure 6(a), ∗∗
p < 0:01). To further validate this, immunohistochemistry
revealed a notable upregulation (Figure 6(b)). Consistent with
the upregulated Nrf2 expression, there was a signiﬁcant
increase in the expression of the downstream antioxidant
HO-1 (Figure 6(c), ∗ p < 0:05), also validated by immunohistochemistry (Figure 6(d)). Compared with PTZ, Carveol significantly upregulated hippocampal and cortical expression of
Nrf2 and HO-1 (Figures 6(a)–6(d)). However, ATRA-treated
groups exhibited blockade of carveol-mediated upregulation
of the innate antioxidants Nrf2 and HO-1, which suggested
that the Nrf2/HO-1 signaling pathway is involved in the antioxidant potential of carveol.
3.5. Carveol Ameliorates Inﬂammatory Mediators via the
Nrf2 Signaling Pathway. Numerous studies have shown that

PTZ-kindling is associated with an intensiﬁed inﬂammatory
cascade. Therefore, we proceeded to determine whether carveol treatment could aﬀect neuroinﬂammation. TNF-α, an
inﬂammatory cytokine, was highly expressed in the kindled
model as evaluated both by ELISA (Figure 7(a), cortex: ∗ p
< 0:05, hippocampus: ∗ p < 0:05) and by immunohistochemistry (Figure 7(b), cortex, CA1: ∗ p < 0:05; CA3: ∗∗ p < 0:01;
DG: ∗∗∗ p < 0:001). As part of downstream targets, we evaluated p-NF-κB and COX-2 expression. The PTZ-treated
group showed elevated p-NF-κB expression as shown by
ELISA (Figure 7(c), cortex: ∗ p < 0:05, hippocampus: ∗∗∗ p <
0:001) and by immunohistochemistry (Figure 7(d), ∗∗∗ p <
0:001). A similar expression pattern was also observed for
COX2 by ELISA (Figure 7(e), cortex: ∗∗ p < 0:01, hippocampus: ∗∗∗ p < 0:001).
Additionally, AChE levels were measured given the
involvement of the cholinergic system in neuroinﬂammation.
Compared with the saline group, the PTZ-treated group
showed a signiﬁcant upregulation of AChE levels
(Figure 7(f), cortex: ∗∗ p < 0:01, hippocampus: ∗∗∗ p < 0:001).
Carveol pretreatment remarkably attenuated expression of
TNF-α (Figures 7(a) and 7(b)), p-NF-κB (Figures 7(c) and
7(d)), COX-2 (Figure 7(e)), and AChE (Figure 7(f)) in both
the cortex and hippocampus. When cotreatment with ATRA
and PTZ exaggerated the neuroinﬂammatory markers, carveol treatment could not reverse the deleterious eﬀects of
PTZ in the ATRA-treated groups.
3.6. Carveol Improves BBB Disruption through Growth
Factors. Previous studies have demonstrated the induction
of growth factors such as vascular endothelial growth factor
(VEGF) in seizures due to BBB disruption. Consistently,
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Figure 7: Eﬀect of carveol on outcomes of PTZ-induced inﬂammatory mediators. (a) TNF-alpha protein expression as quantiﬁed by ELISA.
(b) Immunohistochemistry results for TNF-alpha in the cortical and hippocampal tissues. TNF-α exhibited cytoplasmic localization in
treated brain tissues. (c) p-NF-ΚB protein expression as quantiﬁed by ELISA. (d) Immunohistochemistry results for p-NF-ΚB in the
cortical and hippocampal tissues. p-NF-ΚB exhibited nucleus localization in the treated tissue. (e) COX-2 protein expression as quantiﬁed
by ELISA. (f) Acetylcholinesterase levels in both the cortex and hippocampal tissue. The data were expressed as the mean ± SEM, n = 5
/group in each experiment. ∗∗∗ p < 0:001 shows diﬀerences compared with saline while ####p < 0:001 shows signiﬁcant diﬀerences
compared with PTZ. Scale bar 50 μm, magniﬁcation 40x.

our study demonstrated abrupt VEGF induction following
epileptiform activity in PTZ-treated animals compared with
the saline group (Figure 8, cortex: ∗∗∗ p < 0:001, CA1: ∗ p <
0:05, DG: ∗∗∗ p < 0:001). Carveol attenuated VEGF hyperexpression in all brain regions, which successfully restored
brain permeability (Figure 8, cortex: ##p < 0:01, DG:
#
p < 0:05). On the other hand, ATRA treatment signiﬁcantly
induced angiogenic factor VEGF, which resulted in BBB dysfunction and diminished the restorative potential of carveol
in the cortex of ATRA-treated groups (Figure 8, cortex:
#
p < 0:05).
3.7. Eﬀect of Carveol on PTZ-Induced Lipid Oxidation and
Oxidative Stress Markers. To assess the neuroprotective

potential of carveol against PTZ-induced oxidative stress
markers, we measured the cortical and hippocampal levels
of various enzymatic and nonenzymatic antioxidants, including SOD, CAT, GST, GSH, and TBARS (Figure 9). Carveol
treatment signiﬁcantly restored the level of these antioxidants in the cortex and hippocampus to varying degrees.
Compared with the saline group, the PTZ-treated group
showed signiﬁcantly lower levels of CAT, SOD, GST, and
GSH (Figures 9(a)–9(d), ∗∗∗ p < 0:001). Contrastingly, compared with the saline group, the PTZ-treated group showed
a marked elevation in LPO levels (Figure 9(e), ∗∗∗ p < 0:001
). Carveol treatment signiﬁcantly increased cortical and hippocampal levels of CAT, SOD, GST, and GSH (Figure 9(a),
##
p < 0:01; Figure 9(b), cortex: ##p < 0:01, hippocampus:
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Figure 8: Carveol improves BBB-disruption through VEGF. Immunohistochemistry results for VEGF in the cortical and hippocampal tissues
exhibited cytoplasmic localization in both brain tissues. Data are expressed as the mean ± SEM, n = 5. ∗∗∗ p < 0:001 shows diﬀerence
compared with saline while ####p < 0:001 shows signiﬁcant diﬀerence compared with PTZ. Scale bar 50 μm, magniﬁcation 40x.

p < 0:001; Figure 9(c), #p < 0:05; Figure 9(d), #p < 0:05).
Conversely, carveol-treated animals demonstrated noticeably
reduced TBARS levels in both the cortex and hippocampus
compared with the PTZ group (Figure 9(e), ###p < 0:001).
Moreover, carveol treatment in ATRA-treated groups demonstrated minimal or no antioxidant eﬀects (Figure 9), which
is consistent with our previous ﬁndings (Figure 6).
###

4. Discussion
Plant-derived natural compounds are consistently employed
against diﬀerent pathological disorders owing to better treatment options and minimum side eﬀects. This is due to their
inherent properties of targeting multiple steps in the pathological cascade. For this purpose, extensive research must
be conducted on phytochemicals before human clinical trials
as neuroprotectants [58]. Previous studies have shown that
carveol is a monoterpene possesses robust antioxidant, antiinﬂammatory, and protective properties in various degenerative models [33, 59]. However, there have been no direct
reports regarding the antiepileptic potential of carveol. This
study investigated the neuroprotective potential of carveol
in a PTZ-induced chronic epilepsy model by ameliorating
cognitive deﬁcits, oxidative stress, and neuroinﬂammation.
Our ﬁndings showed that carveol had signiﬁcant potential
in reverting seizures by augmenting the endogenous Nrf2
antioxidant pathway.
In this study, we used subconvulsive PTZ doses, which is
a well-studied chemical inducer of epileptic seizures that
exerts proconvulsant activity through GABAergic inhibition
and therefore causes an imbalance in inhibitory and excitatory neurotransmission that induces seizures [19, 60, 61].
Carveol treatment attenuated these seizures by decreasing
the seizure intensity and frequency, as well as delaying seizure onset. Hippocampal dysfunction and neuronal hyperexcitability in epileptic seizures are directly associated with
various memory and cognitive impairments [62]. Our ﬁnd-

ings were consistent with previous ﬁndings as a decline in
cognition and memory impairment in PTZ-treated animals
was demonstrated by a signiﬁcant increase in escape latency
and the probe test [63]. However, carveol signiﬁcantly
improved memory deﬁcits, as demonstrated by a shorter
latency time and greater time spent in the target quadrant.
Several studies have reported the involvement of ROS in
the pathophysiology of neurodegenerative diseases including
epilepsy [64, 65]. Likewise, oxidative stress can exacerbate
epilepsy as the brain has limited antioxidants combating
capacity [66]. Moreover, the degree of oxidative damage is
proportional to epileptic episodes [67]. This notion is further
supported by the fact that several clinically used antiepileptic
drugs (AEDs) alleviated ROS in seizure [68], while many
other AEDs exacerbated oxidative damage [69, 70]. Therefore the use of adjunct antioxidants with AEDs can be useful
in the management of epilepsy as demonstrated previously
[71]. Our results were consistent with those of previous studies where PTZ-kindled animals experienced oxidative stress
and revealed diminished levels of SOD, CAT, GST, and
GSH [72, 73]. Carveol augmented these antioxidants and
reduced LPO levels, which may partly account for its neuroprotective ability. The substantial oxidative stress caused by
seizures activates the endogenous antioxidant response pathway, Nrf2, and therefore increases the expression of cytoprotective enzymes and ROS scavengers [74, 75]. The Nrf2
pathway forms an important defense against oxidative insults
in both glial cells and neurons [76–78]. Using Nrf2-knockout
mice, Wang et al. concluded that the Nrf2-ARE pathway is
directly involved in protecting the brain from seizuremediated neuronal damage [79, 80]. In another study, Mazzuferi et al. used gene expression datasets and observed exaggerated Nrf2 mRNA levels in the hippocampus of mice that
initiated spontaneous recurrent seizures [81]. Additionally,
Li et al. conﬁrmed the involvement of the Nrf2-ARE pathway
through nuclear Nrf2 translocation and direct ARE activation
[82]. Another study suggested a strong correlation between
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Figure 9: Eﬀect of carveol on oxidative enzymes (Catalase, SOD, GST, GSH, and LPO) in the cortex and hippocampus. (a) CAT level. (b)
SOD level. (c) GST level. (d) GSH level. (e) LPO level. ∗∗∗ p < 0:001 denotes a signiﬁcant diﬀerence compared with the saline group.
###
p < 0:001 denotes signiﬁcant diﬀerences compared with the PTZ group. n = 7/group. Data are expressed as mean ± SEM.

ARE activation and HO-1 expression [83]. Our ﬁndings are
consistent with these previous ﬁndings and we demonstrated
upregulated Nrf2 expression along with the downstream
inducible HO-1 gene and protein in PTZ-treated animals.
Moreover, carveol treatment led to further augmentation of
these genes and protein levels. However, Nrf2 inhibition
through ATRA abolished these eﬀects, indicating the strong

involvement of the Nrf2 pathway in the cytoprotective nature
of carveol.
Nrf2 pathway activation inhibits proinﬂammatory cytokine release and downregulates the p-NF-κB pathway [26,
27]. Numerous studies have suggested the role of inﬂammatory mediators such as COX-2 and p-NF-κB activation along
with other inﬂammatory cytokines including interleukin-6
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Figure 10: Diagrammatic illustration elaborating the underlying antioxidant and neuroprotective potential of carveol in a PTZ-induced
epilepsy model.

(IL-6), interleukin-1 (IL-1b), and TNF-α that form the basis
of neuronal injury in several neurodegenerative models
including epilepsy [11, 84, 85]. Furthermore, studies have
suggested increased COX-2 induction in the mouse brain after
electrical kindling of hippocampal pyramidal cells [10]. Carveol signiﬁcantly ameliorated the upregulated inﬂammatory
mediators in PTZ-treated animals, which is consistent with
recent ﬁndings regarding the modulatory eﬀect of carveol on
proinﬂammatory cytokines [33, 59]. ATRA treatment further
exacerbated the expression of inﬂammatory markers and abolished the anti-inﬂammatory potential of carveol, which supports our hypothesis that carveol exerts its antiinﬂammatory potential by modulating the Nrf2 pathway.
Moreover, the cholinergic anti-inﬂammatory pathway is
signiﬁcantly involved in the modulation of immune response
and inﬂammation in the brain [86]. This notion is further
supported by the fact that several acetylcholinesterase
(AChE) inhibitors promoted anti-inﬂammatory activities
[82, 87]. Studies have suggested that the local immune
response and inﬂammation are associated with the upregulation of hippocampal AChE levels, resulting in cholinergic
imbalance and epileptogenesis [86]. Studies have shown that
AChE may be an important therapeutic target for adjunct
treatment in epilepsy as numerous AChE-inhibitors were
tested in experimental settings for this purpose as a memory
enhancer [88–90]. Moreover, our ﬁndings suggested
increased brain AChE level, which was signiﬁcantly inhibited
by carveol treatment, and indicated a modulating eﬀect of
carveol on cholinergic transmission.

Studies have shown the association between vascular
malformations and epilepsy, which suggested that subsequent BBB dysfunction could induce neuronal hyperactivity.
Additionally, BBB leakage is associated with excessive angiogenesis induced by VEGF, and this expression is increased in
patients with temporal lobe epilepsy [91]. Similarly, altered
membrane ﬂuidity and enhanced permeability caused by
BBB disruption in epileptic tissue cause angiogenesis and
dysfunctional vascular permeability [92]. Additionally, our
experimental ﬁndings suggested upregulated VEGF expression in epileptic animals, which was ameliorated by carveol
treatment, indicating an improvement in angiogenesis
caused by PTZ.

5. Conclusions
In conclusion, our ﬁndings demonstrated that carveol could
be a potent antioxidant and anti-inﬂammatory drug candidate that can exert neuroprotection in a PTZ-induced animal
epilepsy model. We also demonstrated certain safety aspects
of carveol, and it exhibited a relative safety proﬁle as no
impairment was observed in the kidneys, heart, liver, and
brain further assisted by biochemical analysis. Furthermore,
we demonstrated the involvement of the Nrf2-pathway in
the neuroprotective activity of carveol (Figure 10). Additionally, we observed the potential of carveol to negatively modulate inﬂammatory mediators, angiogenic factors, and
cholinergic imbalance; however, still, further experimentation is required to unveil its exact mechanism in epilepsy.
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